Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents.
Antimicrob Agents Chemother. 2014 Oct;58(10):6251-4
Authors: Lin G, Pankuch G, Appelbaum PC, Kosowska-Shick K
Oritavancin exhibited in vitro activity against 169 strains of vancomycin-susceptible, methicillin-resistant Staphylococcus aureus (MRSA) with MICs ranging from 0.03 to 1 μg/ml and against vancomycin-intermediate MRSA (VISA; n = 29), heterogeneous vancomycin-intermediate MRSA (hVISA; n = 5), and vancomycin-resistant MRSA (n = 5) strains, with MICs ranging from 0.12 to 4 μg/ml. For 10 MRSA isolates comprising 5 VISA and 5 hVISA strains, synergy between oritavancin and gentamicin, linezolid, or rifampin was observed against most of the strains tested using a time-kill method.
PMID: 25022588 [PubMed - indexed for MEDLINE]